Rakovina Therapeutics Inc. (FRA:7JO0)

Market Cap	5.27M +55.6%
Revenue (ttm)	n/a
Net Income	-4.32M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,400
Open	0.1038
Previous Close	0.0956
Day's Range	0.1038 - 0.1042
52-Week Range	0.0420 - 0.1900
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 1, 2026

About Rakovina Therapeutics

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor c...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Kim Oishi
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7JO0

Financial Performance

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error